These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 38336206)

  • 1. Letter to the Editor on Cross-Protection of RotaTeq.
    Carias C; Hartwig S; Kanibir N; Matthijnssens J; Tu Y
    J Pediatr; 2024 May; 268():113952. PubMed ID: 38336206
    [No Abstract]   [Full Text] [Related]  

  • 2. Reply to the Letter to the Editor regarding cross-protection of RotaTeq.
    Zeng M; Ma WJ
    J Pediatr; 2024 May; 268():113953. PubMed ID: 38336202
    [No Abstract]   [Full Text] [Related]  

  • 3. Development of a rotavirus vaccine: clinical safety, immunogenicity, and efficacy of the pentavalent rotavirus vaccine, RotaTeq.
    Ciarlet M; Schödel F
    Vaccine; 2009 Dec; 27 Suppl 6():G72-81. PubMed ID: 20006144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spotlight on pentavalent rotavirus vaccine (RotaTeq) in the prevention of rotavirus gastroenteritis in Europe.
    Plosker GL
    BioDrugs; 2010 Dec; 24(6):411-4. PubMed ID: 21043548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rotavirus VP6 as a potential vaccine candidate.
    Afchangi A; Jalilvand S; Mohajel N; Marashi SM; Shoja Z
    Rev Med Virol; 2019 Mar; 29(2):e2027. PubMed ID: 30614135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccination with 3-dose paediatric rotavirus vaccine (RotaTeq®): impact on the timeliness of uptake of the primary course of DTPa vaccine.
    Wendy B
    Vaccine; 2012 Jul; 30(35):5293-7. PubMed ID: 22575163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Results from a randomized clinical trial of coadministration of RotaTeq, a pentavalent rotavirus vaccine, and NeisVac-C, a meningococcal serogroup C conjugate vaccine.
    Vesikari T; Karvonen A; Borrow R; Kitchin N; Baudin M; Thomas S; Fiquet A
    Clin Vaccine Immunol; 2011 May; 18(5):878-84. PubMed ID: 21389149
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vaccine coverage and compliance in Mexico with the two-dose and three-dose rotavirus vaccines.
    Luna-Casas G; Juliao P; Carreño-Manjarrez R; Castañeda-Prado A; Cervantes-Apolinar MY; Navarro-Rodriguez R; Sánchez-González G; Cortés-Alcalá R; DeAntonio R
    Hum Vaccin Immunother; 2019; 15(6):1251-1259. PubMed ID: 30380975
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RotaTeq vaccine adverse events and policy considerations.
    Geier DA; King PG; Sykes LK; Geier MR
    Med Sci Monit; 2008 Mar; 14(3):PH9-16. PubMed ID: 18301365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rotavirus VP6 preparations as a non-replicating vaccine candidates.
    Jalilvand S; Marashi SM; Shoja Z
    Vaccine; 2015 Jun; 33(29):3281-7. PubMed ID: 26021725
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of cost-effectiveness of live oral pentavalent reassortant rotavirus vaccine introduction in Ghana.
    Abbott C; Tiede B; Armah G; Mahmoud A
    Vaccine; 2012 Mar; 30(15):2582-7. PubMed ID: 22321664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic diversity of G1P[8] rotavirus VP7 and VP8* antigens in Finland over a 20-year period: No evidence for selection pressure by universal mass vaccination with RotaTeq® vaccine.
    Hemming M; Vesikari T
    Infect Genet Evol; 2013 Oct; 19():51-8. PubMed ID: 23831933
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pentavalent rotavirus vaccine (RotaTeq): a review of its use in the prevention of rotavirus gastroenteritis in Europe.
    Plosker GL
    Drugs; 2010 Jun; 70(9):1165-88. PubMed ID: 20518582
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of vaccine-derived rotavirus strains in nonimmunocompromised children up to 3-6 months after RotaTeq® vaccination.
    Markkula J; Hemming M; Vesikari T
    Pediatr Infect Dis J; 2015 Mar; 34(3):296-8. PubMed ID: 25260041
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does a monovalent inactivated human rotavirus vaccine induce heterotypic immunity? Evidence from animal studies.
    Jiang B; Wang Y; Glass RI
    Hum Vaccin Immunother; 2013 Aug; 9(8):1634-7. PubMed ID: 23744507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of potential protective mechanisms on the development of live rotavirus vaccines.
    Ward RL; Clark HF; Offit PA
    J Infect Dis; 2010 Sep; 202 Suppl():S72-9. PubMed ID: 20684721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prenatal vitamin A deficiency impairs adaptive immune responses to pentavalent rotavirus vaccine (RotaTeq®) in a neonatal gnotobiotic pig model.
    Kandasamy S; Chattha KS; Vlasova AN; Saif LJ
    Vaccine; 2014 Feb; 32(7):816-24. PubMed ID: 24380684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effectiveness of rotavirus pentavalent vaccine under a universal immunization programme in Israel, 2011-2015: a case-control study.
    Muhsen K; Anis E; Rubinstein U; Kassem E; Goren S; Shulman LM; Ephros M; Cohen D
    Clin Microbiol Infect; 2018 Jan; 24(1):53-59. PubMed ID: 28442435
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improving rotavirus vaccine coverage: Can newer-generation and locally produced vaccines help?
    Deen J; Lopez AL; Kanungo S; Wang XY; Anh DD; Tapia M; Grais RF
    Hum Vaccin Immunother; 2018 Feb; 14(2):495-499. PubMed ID: 29135339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distribution of rotavirus genotypes after introduction of rotavirus vaccines, Rotarix® and RotaTeq®, into the National Immunization Program of Australia.
    Kirkwood CD; Boniface K; Barnes GL; Bishop RF
    Pediatr Infect Dis J; 2011 Jan; 30(1 Suppl):S48-53. PubMed ID: 21183840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.